PROSTATE CANCER PIPELINE REPORT Nov. 20, 2013
Phase III or Application Pending
cabozantinib / Cometriq / XL184 approved for thyroid cancer / Phase III prostate cancer est.2014?
custirsen sodium (OGX-011) Phase III (Aug.2012) blocks clusterin, cell survival protein (fast track) OncoGenex
Prostvac / Prostvacf vaccine in trials Phase III (Nov.2011) aka PSA-tricom vaccine (fast track) Bavarian Nordic (2015?)
Tasquinimod (TASQ) Phase III (2010) prostate cancer anti-angiogenesis med Active Biotech (2016?)
orteronel / TAK-700 androgen synthesis inhibitor in trials Phase III (2012) CYP-17 target Takeda Pharm.
ProstAtak vaccine by injection into prostate Phase III (Sep.2011) with radiation Advantagene
ARN509 Phase 3 (Sept.2013) androgen receptor agonist ( JNJ from Aragon) est.2017-2018?
DCVax®-Prostate autologous vaccine suspended pending partner financing
Phase IIODM-201 androgen receptor agonist early Phase II
PSMA ADC Phase II antibody drug conjugate (ADC) with chemo/ poison
OGX-427 heat shock 27 inhibitor Phase II prostate cancer with prednisone
galeterone / TOK-001 Phase II CYP-17 target plus androgen receptor antagonist
Capesaris (GTx-758), oral nonsteroidal estrogen receptor agonist early Phase II
AEZS-108 Phase II targeted therapy with cell poison
NX-1207 injection into prostate tissue Phase II early cancer, Phase III for BPH
PX-866 inhibitor of the PI-3-kinase Phase II prostate cancer
CV9104, the RNActive cancer vaccine Phase IIb Germany
MLN8237 oral med for neuroendocrine or mcrpc prostate cancer Phase II began Feb. 2013
BIND-014 nanoparticle with docetaxel / Taxotere Phase II in USA
CV9104 immunotherapy CureVac Germany
177Lu-J591 radio-immunotherapy in trials PSMA target
Phase IDSTP3086S anti-STEAP1 ADC Phase I prostate cancer (Zimac trial) Roche
APC-100 Phase I/II APC-300 preclinical
INK128 in trials mtor inhibitor Phase I prostate cancer
Ad5-CMV-NIS gene therapy plus radioactive iodine Phase I Mayo Clinic
Kevetrin / Thioureidobutyronitrile P53 target in Phase I solid tumors
OTS167 to fight cancer stem cells
INO-5150 PSMA vaccine to enter Phase I/II trials Inovio / Roche
BPX-201 dendritic vaccine plus booster drug Bellicum Pharm.
MISC.JX-594 virus that infects/kills cancer cells Phase II some cancers.
ganetespib heat-shock 90 treatment in Phase III some cancers
There are many lesser known meds in trials for prostate cancer.
There are scores of trials for new meds for solid tumors and unspecified cancers.
Post Edited (robertC) : 2/3/2014 2:15:55 PM (GMT-7)